KRAS G12C

Overview

KRAS G12C refers to a specific oncogenic missense variant of the KRAS gene in which glycine at codon 12 is replaced by cysteine. This alteration affects the KRAS small GTPase, a central regulator of signaling pathways that control cell proliferation, survival, and differentiation, including downstream MAPK1-related signaling. In cancer biology, KRAS G12C is notable because the introduced cysteine creates a chemically addressable residue that has enabled the development of allele-specific covalent inhibitors, transforming KRAS from a long-considered undruggable target into a clinically actionable one 42384131Jul41340466Dec.

Therapeutically, KRAS G12C has become an important target in tumors driven by KRAS-dependent signaling, especially lung adenocarcinoma and colorectal cancer, and it is also being investigated in gastrointestinal tumors and pancreatic cancer models. Current research emphasizes direct KRAS G12C inhibition, combination strategies with EGFR blockade, SOS1 inhibition, and approaches to overcome acquired resistance. Resistance remains a major challenge, with both genetic and non-genetic mechanisms reported in the setting of KRAS inhibition 42167227May42276046Jun42270775Jun.

Recent Publications Summary

Recent studies continue to expand the therapeutic arsenal targeting KRAS G12C through both novel inhibitor discovery and clinical advancement. Beyond the approved covalent inhibitors sotorasib and adagrasib, researchers have developed structurally diverse KRAS G12C inhibitors with improved properties. A property-biased DNA-encoded library screening approach identified AM-8719, a CNS-penetrant covalent inhibitor with 200-fold improved potency over initial screening hits and enhanced brain exposure compared to approved agents 42593915Aug. Parallel efforts have pursued noncovalent KRAS inhibitors to overcome the limitations of covalent approaches targeting G12C, with virtual screening campaigns identifying small molecules exhibiting single-digit nanomolar binding affinity and sub-to-low micromolar cell proliferation inhibition in pancreatic cancer lines 42359553Jun. Drug repurposing has also yielded candidates, with computational screening identifying nilotinib and risperidone as high-affinity MAPK pathway targets that markedly reduced NSCLC cell viability and angiogenesis 42595781Aug. In the clinic, glecirasib (JAB-21822) demonstrates promising efficacy in solid tumors with KRAS G12C mutations, though primary and acquired resistance rates of 5.61% and 9.64% respectively remain barriers 42384131Jul. Most notably, the pan-RAS inhibitor daraxonrasib virtually doubled median overall survival (13.2 vs. 6.6 months) in second-line metastatic pancreatic ductal adenocarcinoma, establishing a new treatment standard 42571010Aug.

Intrinsic and acquired resistance to KRAS G12C inhibitors represents a critical therapeutic challenge. Mechanistic studies have identified amphiregulin-mediated EGFR phosphorylation as a pivotal resistance mechanism in both KRAS G12C-mutant NSCLC cell models and leptomeningeal carcinomatosis metastases 42393288Jul. Metabolic reprogramming via ATF3-driven asparagine biosynthesis emerges as a convergence point of resistance, with ATF3 upregulation and asparagine synthetase transactivation enabling tumor escape from KRAS G12C inhibition 42270775Jun. Colorectal cancer tumors exhibit regionally distinct genomic and transcriptomic adaptive responses to KRAS G12C inhibition, including epithelial cell state changes, mesenchymal and YAP-driven signatures, and pro-inflammatory pathway enrichment 42276046Jun42167227May. Resistance also manifests through dysregulated proteolysis machinery when KRAS is targeted for degradation via PROTACs 42200804May, and through increased proportions of epithelial/mesenchymal mixed circulating tumor cells at disease progression 42384131Jul. Farnesylation-driven liquid-liquid phase separation of KRAS enhances its signaling and promotes tumor growth, with evidence that this mechanism contributes to treatment response 42202789May.

Combination strategies have emerged as a rational approach to overcome resistance and enhance therapeutic efficacy. KRAS G12C inhibitors combined with EGFR tyrosine kinase inhibitors suppress tumor growth more effectively than monotherapy 42393288Jul, while pairing with PERK inhibition overcomes ATF3-mediated asparagine metabolic resistance 42270775Jun. CNS-penetrant SOS1 inhibitors synergize with KRAS G12C inhibitors in mouse tumor models, producing deeper and more sustained reductions in downstream signaling markers including DUSP6 mRNA and phosphorylated ERK 42301273Jun. Highly potent SOS1 inhibitors (78b and 78d) demonstrate submicromolar antiproliferative activity across colorectal cancer cell panels and significant tumor growth inhibition (75.1% and 86.2%) in xenograft models 42247371Jun. In pancreatic cancer, allele-specific strategies pair KRAS G12D inhibitors with anti-PD-L1 or Nectin-4-targeted antibody-drug conjugates, while farnesyl transferase co-inhibition with darlifarnib plus adagrasib successfully bypasses adaptive resistance in the KRAS G12C setting 42571010Aug. Statins, particularly pitavastatin, disrupt KRAS phase separation by inhibiting farnesylation and enhance KRAS G12C inhibitor efficacy in colorectal cancer 42202789May.

Off-target profiling and mechanistic characterization continue to refine understanding of KRAS G12C inhibitor biology. Stability-based proteomics including SPROX and thermal protein profiling identified aldehyde dehydrogenase 1A3 (ALDH1A3) as a reproducible off-target of the covalent inhibitor ARS-1620, with covalent modification at C314 and dose-dependent enzymatic inhibition 42275002Jun. Clinical data support the efficacy of KRAS G12C inhibitors across diverse malignancies; sotorasib and adagrasib demonstrate activity in pediatric tumors harboring KRAS G12C mutations and cross-reactivity against HRAS G12C and NRAS G12C, with downstream ERK phosphorylation inhibition 41340466Dec. Active fragment assembly strategies have yielded additional KRAS inhibitors such as compound 10b, which inhibits both KRAS G12C and KRAS G12D mutations in pancreatic cancer cells with favorable selectivity for malignant over non-cancerous cells 41931988Apr. Collectively, these studies demonstrate that while KRAS G12C inhibitors represent a therapeutic breakthrough, particularly in NSCLC and emerging applications in pancreatic and colorectal Cancers, addressing resistance mechanisms through mechanistic understanding and rational combination approaches remains essential for improving clinical outcomes.

What Changes, What Holds

1. CNS-penetrant and noncovalent KRAS G12C inhibitors establish therapeutic approaches that bypass covalent-targeting constraints
NEW DIRECTION AM-8719's 200-fold improved potency and brain exposure 42593915Aug and noncovalent inhibitors with single-digit nanomolar affinity 42359553Jun extend the therapeutic reach beyond sotorasib and adagrasib. Daraxonrasib's near-doubling of overall survival in metastatic pancreatic cancer 42571010Aug establishes a new clinical standard, moving beyond the direct covalent inhibition the Overview emphasizes as current research. The Overview covers only approved covalent inhibitors; these findings expand both chemical strategy and efficacy threshold.

2. Amphiregulin-EGFR signaling and ATF3-asparagine synthesis establish mechanistic nodes of resistance convergence
REINFORCES Amphiregulin-mediated EGFR phosphorylation drives resistance in NSCLC and leptomeningeal disease 42393288Jul, while ATF3-driven asparagine biosynthesis emerges as a convergence point enabling escape from KRAS G12C inhibition 42270775Jun. Farnesylation-driven phase separation of KRAS itself promotes signaling and resistance 42202789May. The Overview acknowledges that resistance involves both genetic and non-genetic mechanisms; these studies provide mechanistic detail supporting rather than contradicting the baseline observation of resistance as a persistent challenge.

3. Pairing KRAS G12C inhibitors with EGFR, PERK, and farnesyltransferase inhibitors achieves superior tumor control through mechanism-specific resistance bypass
REINFORCES EGFR TKI co-treatment suppresses growth more effectively than monotherapy 42393288Jul, PERK inhibition overcomes ATF3-mediated resistance 42270775Jun, and CNS-penetrant SOS1 inhibitors produce deeper ERK suppression 42301273Jun. statin-driven KRAS phase separation disruption enhances efficacy 42202789May, while farnesyl transferase co-inhibition with adagrasib bypasses adaptive resistance in pancreatic cancer 42571010Aug. The Overview identifies combination strategies with EGFR and SOS1 as research priorities; this work sharpens mechanistic rationale and expands the combination palette.

4. Off-target engagement and cross-RAS reactivity reveal unexpected properties of sotorasib and adagrasib beyond allele-specific KRAS G12C inhibition
NEW DIRECTION ARS-1620 covalently engages ALDH1A3 42275002Jun, while sotorasib and adagrasib cross-react against HRAS G12C and NRAS G12C in pediatric tumors 41340466Dec, and fragment assembly has yielded inhibitors targeting both KRAS G12C and KRAS G12D 41931988Apr. The Overview presents these approved drugs as allele-specific KRAS G12C inhibitors; off-target liabilities and unexpected RAS mutant recognition materially change their understood selectivity profile and safety footprint, though they remain clinically actionable.

Overview update candidates: Daraxonrasib's near-doubling of overall survival in metastatic pancreatic cancer and the emergence of CNS-penetrant and noncovalent KRAS G12C inhibitors merit inclusion as established alternatives to approved covalent inhibitors. Off-target engagement and cross-RAS reactivity of sotorasib and adagrasib should be documented as selectivity nuances.